TrialA Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Trial details
- Registry ID
- NCT07221500
- Phase
- Phase 2
NRIX
Nurix Therapeutics, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
2Trials in this database
3Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)NCT07221500 | NRIX | Phase 2 | Recruiting | 2028-01Estimated |
| Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLLNCT07516093 | NRIX | Phase 3 | Recruiting | 2029-10Estimated |
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
Trial details
- Registry ID
- NCT07516093
- Phase
- Phase 3
Latest recorded trial changes
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
NCT07516093 · Nurix Therapeutics, Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Progression-free survival (PFS) as assessed by Independent Review Committee (IRC)
+ After
Measure: Progression-free survival (PFS) as assessed by Independent Review Committee (IRC) Measure: Objective response rate (ORR) without partial response with lymphocytosis (PR-L) as assessed by IRC
Recruitment status changed
− Before
Not yet recruiting
+ After
Recruiting
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
NCT07221500 · Nurix Therapeutics, Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Objective response rate as determined by an Independent Review Committee (IRC)
+ After
Measure: Objective response rate without partial response with lymphocytosis (PR-L) as determined by an Independent Review Committee (IRC)